MX337468B - Anticuerpos anti notch-1. - Google Patents
Anticuerpos anti notch-1.Info
- Publication number
- MX337468B MX337468B MX2011013717A MX2011013717A MX337468B MX 337468 B MX337468 B MX 337468B MX 2011013717 A MX2011013717 A MX 2011013717A MX 2011013717 A MX2011013717 A MX 2011013717A MX 337468 B MX337468 B MX 337468B
- Authority
- MX
- Mexico
- Prior art keywords
- epitope
- antibodies
- notch1
- nrr
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un método para preparar una masa de pan fermentada, el método comprende la siguiente secuencia de pasos de procesamientos: a) combinar harina, agua, levadura y/o agente de fermentación y opcionalmente uno o más ingredientes de panadería adicionales para producir una mezcla de tipo masa; b) mezclar y trabajar la mezcla de tipo masa en una mezclador a para producir una masa subdesarrollada con una densidad de 0.9-1.5 g/ml, la entrada de energía total de la mezcladora en la masa subdesarrollada durante el mezclado y el trabajo de la mezcla de tipo masa es por lo menos 1 W.h/Kg; c) trabajar adicionalmente un lote de por lo menos 15 kg de masa subdesarrollada al someterla a esfuerzo cortante de deformación, produciendo de ese modo una masa desarrollada; d) dividir la masa desarrollada en dos o más piezas de masa desarrollada que tienen una masa individual de 30-3000 g; y e) fermentar las piezas de masa desarrollada para generar piezas de masa fermentada que tienen un volumen específico de por lo menos 2.0 ml/g; en donde la secuencia mencionada anteriormente de pasos de procesamiento se completa dentro de 3 horas. El presente proceso emplea trabajo de alta energía para producir una masa subdesarrollada, seguido de trabajo de baja energía para desarrollar adicionalmente la masa. Al emplear una combinación de trabajo de alta energía y trabajo de baja energía, la energía de trabajo total necesaria para la preparación de una masa completamente desarrollada se puede reducir sustancialmente. Al mismo tiempo, esta combinación de condiciones de trabajo produce una masa que después del horneado genera una migaja muy suave con una estructura de migaja extremadamente regular. La invención proporciona además una barra de pan de mole que tiene una estructura celular única que se puede obtener por medio del método mencionado anteriormente, así como también un aparato para operar el método mencionado anteriormente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21819309P | 2009-06-18 | 2009-06-18 | |
PCT/IB2010/052711 WO2010146550A1 (en) | 2009-06-18 | 2010-06-16 | Anti notch-1 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011013717A MX2011013717A (es) | 2012-05-29 |
MX337468B true MX337468B (es) | 2016-03-02 |
Family
ID=42575817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011013717A MX337468B (es) | 2009-06-18 | 2010-06-16 | Anticuerpos anti notch-1. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9090690B2 (es) |
EP (2) | EP2443151A1 (es) |
JP (2) | JP6059985B2 (es) |
KR (1) | KR101570898B1 (es) |
CN (1) | CN102686610A (es) |
AU (1) | AU2010261364B2 (es) |
BR (1) | BRPI1011805A2 (es) |
CA (1) | CA2765989C (es) |
CO (1) | CO6480924A2 (es) |
IL (1) | IL217066A0 (es) |
MX (1) | MX337468B (es) |
NZ (1) | NZ597611A (es) |
PE (1) | PE20121494A1 (es) |
RU (1) | RU2011151287A (es) |
SG (1) | SG176731A1 (es) |
WO (1) | WO2010146550A1 (es) |
ZA (1) | ZA201109282B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101712214B1 (ko) * | 2008-10-01 | 2017-03-03 | 제넨테크, 인크. | 항-노치2 항체 및 사용 방법 |
US9090690B2 (en) | 2009-06-18 | 2015-07-28 | Pfizer Inc. | Anti Notch-1 antibodies |
WO2011041336A2 (en) * | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Methods of treating cancer using notch antagonists |
WO2012080891A1 (en) * | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
US9127060B2 (en) * | 2010-12-15 | 2015-09-08 | Wyeth Llc | Anti-Notch1 antibodies |
TW201726746A (zh) | 2012-11-07 | 2017-08-01 | 輝瑞股份有限公司 | 抗切口3(anti-notch3)抗體及抗體-藥物共軛體 |
WO2015134627A1 (en) * | 2014-03-07 | 2015-09-11 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch1 antibodies |
CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
US11026996B2 (en) * | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
WO2020045646A1 (ja) | 2018-08-31 | 2020-03-05 | Bloom Technology 株式会社 | 終末糖化産物に対する抗体およびその使用 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8421551D0 (en) | 1984-08-24 | 1984-09-26 | Ici Plc | Water-soluble dye |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
JP2698529B2 (ja) | 1993-04-06 | 1998-01-19 | 浜松ホトニクス株式会社 | イメージインテンシファイア装置 |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US7399633B2 (en) | 2000-10-27 | 2008-07-15 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20030148954A1 (en) | 2001-11-02 | 2003-08-07 | Wisconsin Alumni Research Foundation | Agents and methods for modulating activator protein-1-mediated cellular processes |
WO2003042246A2 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
EP1544210A4 (en) | 2002-07-18 | 2006-01-25 | Masayasu Okochi | NEW NOTCH ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS FOR WHICH THEY ARE USED |
PT2270048E (pt) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
JP2007512348A (ja) | 2003-11-26 | 2007-05-17 | ヘルス リサーチ インコーポレイテッド | 形質細胞の治療のためのノッチ経路干渉剤の使用 |
US20080220416A1 (en) | 2004-05-20 | 2008-09-11 | The Board Of Trustees Of The University Of Illinoi | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof |
US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006092062A1 (en) | 2005-03-04 | 2006-09-08 | The Hospital For Sick Children | Methods for cancer prognosis |
US7100777B1 (en) * | 2005-07-07 | 2006-09-05 | Jui-Chien Kao | Hanger rack for hand tools |
US20070072222A1 (en) | 2005-09-23 | 2007-03-29 | Franziska Boess | FABP4 as biomarker for toxic effect |
WO2007061988A2 (en) | 2005-11-22 | 2007-05-31 | University Of Vermont And State Agricultural College | Methods for determining notch signaling and uses thereof |
WO2008057144A2 (en) | 2006-05-15 | 2008-05-15 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1 |
CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US20100062012A1 (en) | 2007-03-05 | 2010-03-11 | Ioannides Constantin G | Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
PL2307459T3 (pl) | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
US9090690B2 (en) * | 2009-06-18 | 2015-07-28 | Pfizer Inc. | Anti Notch-1 antibodies |
WO2011041336A2 (en) | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Methods of treating cancer using notch antagonists |
ES2561102T3 (es) | 2010-01-13 | 2016-02-24 | Oncomed Pharmaceuticals, Inc. | Agentes de unión a Notch1 y procedimientos de uso de los mismos |
US9127060B2 (en) | 2010-12-15 | 2015-09-08 | Wyeth Llc | Anti-Notch1 antibodies |
WO2012080891A1 (en) | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
-
2010
- 2010-06-16 US US13/378,791 patent/US9090690B2/en active Active
- 2010-06-16 EP EP10730230A patent/EP2443151A1/en not_active Withdrawn
- 2010-06-16 KR KR1020127001293A patent/KR101570898B1/ko not_active IP Right Cessation
- 2010-06-16 CA CA2765989A patent/CA2765989C/en not_active Expired - Fee Related
- 2010-06-16 EP EP18172657.1A patent/EP3431501A1/en not_active Withdrawn
- 2010-06-16 SG SG2011090800A patent/SG176731A1/en unknown
- 2010-06-16 AU AU2010261364A patent/AU2010261364B2/en not_active Ceased
- 2010-06-16 RU RU2011151287/10A patent/RU2011151287A/ru not_active Application Discontinuation
- 2010-06-16 WO PCT/IB2010/052711 patent/WO2010146550A1/en active Application Filing
- 2010-06-16 CN CN2010800367326A patent/CN102686610A/zh active Pending
- 2010-06-16 BR BRPI1011805A patent/BRPI1011805A2/pt not_active IP Right Cessation
- 2010-06-16 PE PE2011002114A patent/PE20121494A1/es not_active Application Discontinuation
- 2010-06-16 MX MX2011013717A patent/MX337468B/es active IP Right Grant
- 2010-06-16 JP JP2012515616A patent/JP6059985B2/ja not_active Expired - Fee Related
- 2010-06-16 NZ NZ597611A patent/NZ597611A/en not_active IP Right Cessation
-
2011
- 2011-12-15 ZA ZA2011/09282A patent/ZA201109282B/en unknown
- 2011-12-18 IL IL217066A patent/IL217066A0/en unknown
- 2011-12-22 CO CO11177186A patent/CO6480924A2/es active IP Right Grant
-
2016
- 2016-01-14 JP JP2016004952A patent/JP2016121162A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG176731A1 (en) | 2012-01-30 |
JP2016121162A (ja) | 2016-07-07 |
CN102686610A (zh) | 2012-09-19 |
RU2011151287A (ru) | 2013-07-27 |
CA2765989A1 (en) | 2010-12-23 |
US20120093813A1 (en) | 2012-04-19 |
KR101570898B1 (ko) | 2015-11-23 |
JP2012530487A (ja) | 2012-12-06 |
JP6059985B2 (ja) | 2017-01-11 |
US9090690B2 (en) | 2015-07-28 |
PE20121494A1 (es) | 2012-11-01 |
KR20120071379A (ko) | 2012-07-02 |
NZ597611A (en) | 2014-03-28 |
EP2443151A1 (en) | 2012-04-25 |
AU2010261364A1 (en) | 2012-01-19 |
IL217066A0 (en) | 2012-02-29 |
ZA201109282B (en) | 2012-08-29 |
CO6480924A2 (es) | 2012-07-16 |
CA2765989C (en) | 2016-11-29 |
BRPI1011805A2 (pt) | 2016-10-11 |
WO2010146550A1 (en) | 2010-12-23 |
MX2011013717A (es) | 2012-05-29 |
AU2010261364B2 (en) | 2015-05-07 |
EP3431501A1 (en) | 2019-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX337468B (es) | Anticuerpos anti notch-1. | |
MX2019014265A (es) | Tratamientos conjuntos triples con anticuerpos. | |
MX2019001355A (es) | Anticuerpos monoclonales multiespecíficos. | |
CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
NZ629913A (en) | Anti-ox40 antibodies and methods of using the same | |
EP3702372A3 (en) | Anti-cd40 human antibodies | |
MX2017006233A (es) | Celula. | |
NZ616382A (en) | Antibodies specific to cadherin-17 | |
MX2020009634A (es) | Anticuerpos y metodos de uso. | |
BRPI1013428A2 (pt) | anticorpos humanizados para axl | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
NZ586754A (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
BR112014019331A8 (pt) | anticorpos para cd47 e métodos de uso desses | |
IL222359A0 (en) | Monoclonal antibodies against her2 antigens, and uses therefor | |
MX2014000363A (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
NZ611785A (en) | Anti-notch1 antibodies | |
EP3029069A4 (en) | Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof | |
WO2015051320A3 (en) | Anti-sox10 antibody systems and methods | |
WO2013115410A3 (en) | Anti-phospholipase d4 antibody | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
WO2014145961A3 (en) | Hybridoma clones and monoclonal antibodies to tetraspanin 8 | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |